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silent cerebral infarct (SCI) and stroke in diabetic patients younger than 60 years who did not have other clinical
evidence of AF and cerebrovascular disease at baseline.Background In type 2 diabetic patients, one-fourth of strokes are of unknown cause, and subclinical episodes of AF may be
a common etiologic factor.Methods A total of 464 type 2 diabetic patients younger than 60 years were included in a longitudinal observational study and
matched to patients without diabetes. Patients underwent 48-h electrocardiographic Holter monitoring quarterly to
detect brief subclinical episodes of AF (duration of AF <48 h) and were followed up for 37 months. The outcomes
were SCI, assessed by magnetic resonance imaging of the brain, and stroke events during the follow-up period.Results The prevalence of subclinical episodes of AF was signiﬁcantly greater among patients with diabetes compared with
matched healthy subjects (11% vs. 1.6%, p < 0.0001). During an average duration of 37 months, 43 stroke events
occurred in the diabetic population and no events occurred in healthy subjects. Diabetic patients with silent episodes
of AF (n ¼ 176) had a higher baseline prevalence of SCI (61% vs. 29%; p < 0.01) and a higher number of stroke
events (17.3% vs. 5.9%; p < 0.01) during the follow-up period than the other patients (n ¼ 288). An episode of silent
AF was an independent determinant of SCI (odds ratio: 4.441; p < 0.001; conﬁdence interval: 2.42 to 8.16) and an
independent predictor of the occurrence of stroke in diabetic patients (hazard ratio: 4.6; p < 0.01; conﬁdence
interval: 2.7 to 9.1).Conclusions Subclinical episodes of AF occurred frequently in type 2 diabetic patients and were associated with a signiﬁcantly
increased risk of SCI and stroke. (J Am Coll Cardiol 2013;62:525–30) ª 2013 by the American College of
Cardiology FoundationSee page 540The relative risk of stroke in diabetic patients younger than 60
years is twice that of nondiabetic subjects older than 70 years
(1). Diabetes-related factors (e.g., hyperglycemia, insulin
resistance), diabetes-associated vascular risk factors (e.g.,
hypertension and dyslipidemia), and genetic, demographic,
and lifestyle factors may modulate such risk (2). The contri-
bution of these factors, many of which are strongly interre-
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a doubled risk of stroke comparedwith thosewithout diabetes
(1). Moreover, only 15% of diabetic patients with stroke have
a history of symptomatic atrial ﬁbrillation (AF) (3). Thus,approximately one-fourth of strokes are of unknown cause,
and subclinical AFmay be a common etiologic factor (4). The
risk of AF, a major cause of thromboembolic stroke, is
increased by 40% in diabetic patients (5). Permanent AF, end
stage of progression from paroxysmal forms (6), and silent
paroxysmal AF in patients without previously documented
arrhythmic episodes are associated with at least the same risk
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526of stroke as symptomatic AF (7).
Diabetes is an independent
determinant of AF, and diabetic
patients frequently have asymp-
tomatic (e.g., silent) AF (8,9),
but it is unknown whether
silent episodes of AF inﬂuence
cerebrovascular diseases in dia-
betic patients. In this context, the
identiﬁcation of silent episodes of
AF as a possible cause of excess
stroke in young/adult diabetic
patients may have an important
role in clinical and therapeutic
management.Consequently, thereis a need for more evaluations addressing the path-
ophysiological alterations that underlie the cerebrovascular
diseases and silent episodes of AF in diabetic patients. Our
study prospectively evaluated whether asymptomatic
episodes of AF are more closely related to silent cerebral
infarct (SCI) and stroke events in type 2 diabetic patients who
did not have other evidence of AF or stroke at baseline.
Methods
The study protocol included a recruitment period of 4 years
(from January 1, 2005, to January 1, 2009) and a follow-up
period of 3 years. In the present study, 464 type 2 diabetic
patients (mean age, 52  6 years) were followed up
prospectively for an average of 37 months. These patients
were selected from a larger cohort of type 2 diabetic patients
(N ¼ 1,992) from 4 participating institutions (1 clinic, 2
hospitals, and 1 outpatient clinic). The inclusion criteria were
age younger than 60 years, successful quarterly 48-h elec-
trocardiographic (ECG) Holter monitoring (48HM), and
assessment of the presence/absence of SCI by magnetic
resonance imaging (MRI) of the brain. Patients with any of
the following criteria at initial diagnosis were excluded:
arrhythmia, documented persistent and/or permanent AF,
documented stroke or transient ischemic attack, anti-
coagulation therapy, coronary artery or valvular heart disease,
cardiomyopathy, history of congestive heart failure, hyper-
tension, carotid and peripheral vascular disease, hyperthy-
roidism, chronic obstructive pulmonary disease, obstructive
sleep apnea, and hepatic damage. As a result, 1,528 of the
1,992 screened diabetic patients were excluded and 464 were
included in the study. All selected diabetic patients were
matched to 240 healthy subjects without diabetes (control
group) using anthropometric data. The control group was
recruited at our institution from a study population of healthy
subjects without exclusion criteria. These subjects were
managed to provide anthropometric characteristics compa-
rable to the other groups. All patients studied were ambu-
latory and gave informed consent to participate in the study,
which was approved by the Ethics Committee for Human
Studies at Second University of Naples (Naples, Italy).All selected patients underwent 48-h ambulatory ECG
recording (EVO, Spacelabs Healthcare, Hertford, United
Kingdom) at 3, 6, 9, and 12 months during the screening for
AF and then annually for another 3 years. The system was
fully automatic and computerized; tracings were analyzed by
2 investigators who were unaware of the results of other
investigations. Three ECG leads (modiﬁed leads V1, V5, and
aVF) and a time signal to correct for tape speed irregularities
were recorded. The quarterly 48HM follow-up was per-
formed in all patients to identify silent episodes of AF (10).
Baseline AF was classiﬁed as episode, paroxysmal, persistent,
or permanent. Silent (i.e., asymptomatic) AF may pres-
ent as any of the temporal forms of AF (11). An episode of
AF was deﬁned as a duration of AF <48 h. The duration of
an episode of AF was arbitrarily classiﬁed as follows: 10 min
to 1 h, 1 h to 24 h, and >24 to 48 h (10). The average
duration (hours) of episodes of AF over the whole observa-
tional period was deﬁned as the absolute AF burden. We
classiﬁed the patients according to the presence of silent
episodes of AF (SAFE group, n ¼ 176) and the absence of
silent episodes of AF (non-SAFE group, n ¼ 288). In all
patients, MRI of the brain was performed with a super-
conducting magnet with a main strength of 1.5-T within 30
days of the baseline 48HM (12). T1- and T2-weighted
images were obtained in the transverse plane with 7.8-mm-
thick or 8.0-mm-thick sections. An SCI was deﬁned as a low
signal intensity area (3 to 15 mm) on T1-weighted images
that was also visible as a hyperintense lesion on T2-weighted
images. All SCIs detected were lacunar infarcts with a size
of <15 mm. The MRIs of the subjects were randomly stored
and interpreted without knowledge of the subjects’ names
and characteristics.
Post-screening follow-up of the patients was scheduled
annually for 36 months at our outpatient clinic or at the
referring cardiologists’ ofﬁce. During these visits, 48HM
rhythm documentation and documentation of clinical data as
well as complications were performed. All patients were
treated with aspirin 75 to 325 mg/day; if the CHADS2
(Congestive heart failure, Hypertension, Age 75 years,
Diabetes mellitus, previous Stroke/transient ischemic attack)
score was 2, antiaggregant therapy was switched to oral
anticoagulation therapy (13). Stroke events were diagnosed
by the physician who was caring for the patient at the time of
the event, and independent neurologists reviewed the cases
and conﬁrmed the diagnosis of stroke events. Stroke was
diagnosed on the basis of sudden onset of a neurological
deﬁcit that persisted for >24 h in the absence of any other
disease process that could explain the symptom.
Statistical analysis. Data are expressed asmean SD.Two-
sided unpaired t test and chi-square test were used to test
differences between the groups in the mean values of contin-
uousmeasures and prevalence rates, respectively.Hazard ratios
(HRs) and odds ratios (ORs) with 95% conﬁdence intervals
(CIs) were calculated with Cox proportional hazards regres-
sion models and multiple logistic regression analysis, respec-
tively. In particular, Cox regression multivariate analysis,
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527including sex, body mass index, diastolic blood pressure,
duration of diabetes, plasma glucose level, hemoglobin A1c,
interventricular septum and hyperlipidemia, silent episodes of
AF, systolic blood pressure, and prevalence of SCI as cova-
riates, was performed to identify the independent prognostic
factors for predicting stroke. We used Kaplan-Meier survival
analysis to determine the probability that ictus would occur in
the SAFE and non-SAFE groups, comparing the 2 groups
with the use of the log-rank test. The statistical calculations
were performed using SPSS version 12.0 (SPSS Inc., Chicago,
Illinois). Differences with p < 0.05 were considered to be
statistically signiﬁcant.Results
Cumulative quarterly 48HM (192 h for each patient) showed
a greater prevalence of subclinical episodes of AF among
patients with diabetes (n ¼ 1,992) compared with matched
healthy subjects (n ¼ 240) (11% [n ¼ 212] vs. 1.6% [n ¼ 4];
p < 0.001). Of the 1,992 screened patients with type 2
diabetes, 176 (9%) met the inclusion criteria for silent
episodes of AF and clinical characteristics (SAFE group),
whereas 288 (15%) met the inclusion criteria for only clinical
characteristics (non-SAFE group). Thus, the present study
included 464 type 2 diabetic patients and 240 healthy
subjects. Table 1 shows the baseline characteristics of the
study populations. No signiﬁcant differences in clinical
and anthropometric characteristics were found between the
study groups. Aspirin was used by 99% of the diabetic
patients in both the SAFE and non-SAFE groups and 10%
of the subjects in the control group, and none of the patients
were being treated with a vitamin K antagonist at baseline.
The quarterly 48HM follow-up revealed 12 episodes of silent
AF lasting 10 min to 1 h (39 10 min), 151 episodes lasting
1 to 24 h (12  6 h), and 51 episodes lasting 24 to <48 h
(37  6 h) in diabetic patients in the SAFE group, whereas
only 2 episodes of AF lasting 1 to 24 h were revealed in
healthy subjects. During cumulative quarterly 48HM, the
mean absolute burden of AF was 21  15 h in the 176
patients in the SAFE group and 3  1.4 h in the 2 healthy
subjects with episodes of AF (p < 0.001). SCI was detected
in 190 diabetic patients (41%; n ¼ 464) and only 1 healthy
subject (0.5%). On MRI examination, SCI was more
frequently detected in the SAFE group than in the non-
SAFE group (61% vs. 29%; p < 0.01). Moreover, the
absolute burden of AF was signiﬁcantly correlated with both
size (r ¼ 0.574; p < 0.001) and number of SCIs (r ¼ 0.591;
p < 0.001) (Fig. 1). Multiple logistic regression analysis
demonstrated that episodes of silent AF were associated with
SCI (p ¼ 0.001) as well as left atrial diameter (p ¼ 0.024),
systolic blood pressure (p ¼ 0.002), and duration of diabetes
(p ¼ 0.044), whereas other confounders (sex, body mass
index, diastolic blood pressure, plasma glucose level, hemo-
globin A1c, interventricular septum, and hyperlipidemia)
were again not signiﬁcant (Table 2).After a mean follow-up period of 37.5  1.6 months,
clinical AF developed in 20 patients (11%) with silent
episodes of AF compared with only 13 patients (4%) without
silent episodes of AF (p < 0.01) (Table 1). All patients with
clinical AF were excluded from follow-up analysis. No AF
was diagnosed in healthy subjects. Therefore, the stroke
follow-up was performed in 156 patients in the SAFE group
and 275 patients in the non-SAFE group. Over the course of
the follow-up period, 26 patients in the SAFE group (15%)
and 19 (7%) in the non-SAFE group were treated with
a vitamin K antagonist, including 33 patients who had
developed clinical AF. Despite the use of antiplatelet agents
and a vitamin K antagonist, 43 stroke events occurred during
follow-up. As shown in Figure 2, the cumulative percent of
stroke-free survival was signiﬁcantly lower in patients in the
SAFE group. After 37.5  1.6 months, ischemic stroke
developed in 27 patients in the SAFE group (17.3%)
compared with 16 patients in the non-SAFE group (5.9%)
(p < 0.01). No stroke occurred in healthy subjects. Interim
analysis revealed that the annual incidence of stroke was
higher in patients in the SAFE group compared with
patients in the non-SAFE group during the ﬁrst (3.8% vs.
1.4%; p< 0.05) and second year (6.4% vs. 2.2%; p < 0.05) of
follow-up (Fig. 2). Cox regression analysis revealed that the
presence of silent episodes of AF (HR: 4.6; 95% CI: 2.7 to
9.1; p < 0.001), systolic blood pressure (HR: 1.7; 95% CI:
1.02 to 2.92; p < 0.01), and prevalence of SCI (HR: 3.1;
95% CI: 1.3 to 7.1; p < 0.005) were associated with risk of
stroke, whereas there were no signiﬁcant other confounders
(sex, body mass index, diastolic blood pressure, duration of
diabetes, plasma glucose level, hemoglobin A1c, interven-
tricular septum, and hyperlipidemia). Of the 43 stroke
events, 42 were ischemic and 1 was hemorrhagic.Discussion
The ﬁrst relevant ﬁnding of this study was that type 2
diabetic patients younger than 60 years and without clinical
AF had a signiﬁcant incidence of subclinical brief episodes
of AF. Indeed, cumulative quarterly 48HM showed
a signiﬁcantly greater prevalence of subclinical episodes of
AF among patients with diabetes compared with matched
healthy subjects. Subclinical brief episodes of AF were
detected in approximately one of the hundreds of healthy
subjects within 12 months after quarterly 48HM evaluations
and, in a more marked fashion, in one-tenth of the diabetic
patients.
The second major ﬁnding of the study was that the
presence of brief episodes of AF was associated with an
increased risk of SCI as well as the subsequent development
of stroke in type 2 diabetic patients younger than 60 years of
age independently of duration of diabetes and target organ
damage. The prevalence of SCI was 41% among the diabetic
patients, which is comparable to previous observations
(approximately 42%) (14). As background for such an
Table 1 Characteristics of Study Patients at Baseline and Follow-Up
Baseline 12 Months 24 Months 36 Months
SAFE
Group
Non-SAFE
Group
Control
Group
SAFE
Group
Non-SAFE
Group
Control
Group
SAFE
Group
Non-SAFE
Group
Control
Group
SAFE
Group
Non-SAFE
Group
Control
Group
n 176 288 240 176 288 240 176 288 240 176 288 240
Mean age (yrs) 50  5 51  6 51  9 50  8 52  9 52  7 51  6 53  2 53  8 52  9 53  3 54  2
Male/female 90/86 148/140 65/55 90/86 148/140 65/55 90/86 148/140 65/55 90/86 148/140 65/55
Body mass index
(kg/m2)
30  1.8 30  2.1 29  3.4 29  1.6 30  1.1 29  3.6 30  2.3 29  1.9 30  1.8 30  1.6 30  1.5 30  2.8
Systolic blood
pressure (mm Hg)
131  12 132  15 120  14 129  13 130  18 128  18 129  21 130  16 131  23 130  29 131  19 13 0 24
Diastolic blood
pressure (mm Hg)
79  6 78  7 78  9 80  10 79  9 80  6 79  9 79  6 78  11 81  11 80  9 81  6
Heart rate
(beats/min)
76  8 77  9 77  11 77  8 78  5 76  11 78  9 78  9 76  6 77  4 78  2 76  4
Fasting glucose
(mg/dl)
153  24* 152  22* 86  12 150  26* 151  18* 89  11 151  15* 149  21* 85  4 149  14* 150  18* 88  12
Post-prandial glucose
(mg/dl)
182  26* 181  27* 102  12 177  36* 178  25* 102  12 180  33* 182  18* 103  8 183  44* 183  29* 101  15
Hemoglobin A1c (%) 7.0  0.7* 7.1  0.8* 5.9  0.2 7.0  0.9* 7.0  1.0* 5.8  0.6 7.2  1.1* 7.2  0.9* 6.0  0.2 7.3  1.2* 7.1  1.3* 6.0  0.3
Total cholesterol
(mg/dl)
186  24 187  21 182  33 186  24 187  21 180  32 186  24 187  21 180  30 186  24 187  21 182  32
High-density
lipoprotein
cholesterol
(mg/dl)
38  6* 39  5 41  9 38  6* 39  5 40  10 38  6* 39  5 41  8 38  6* 39  5 40  6
Triglycerides (mg/dl) 182  20* 185  20* 160  14 182  20* 185  20* 160  14 182  20* 185  20* 160  16 182  20* 185  20* 161  17
Duration of
diabetes (yrs)
14  3 15  5 d 14  7 16  1 d 15  8 17  2 d 16  9 17  1 d
Smokers, % (n) 15 (27)* 14 (41)* 30 (50) 12 (21)*y 9 (27)* 18 (44) 10 (18)* 9 (25)* 17 (40) 9 (17)* 8 (23)* 17 (40)
Active therapy, % (n)
Statin 24 (41)* 25 (73)* 10 (26) 25 (43)* 26 (74)* 10 (26) 24 (42)* 25 (73)* 8 (20) 22 (39)* 25 (71)* 9 (22)
Oral antidiabetic
therapy
76 (134) 77 (221) d 76 (133) 77 (222) d 77 (135) 76 (218) d 77 (136) 77 (221) d
Insulin therapy 24 (42) 23 (67) d 25 (44) 24 (70) d 25 (45) 23 (69) d 27 (47) 25 (72) d
Aspirin 99 (174)* 99 (284)* 10 (24) 100 (176)* 99 (286)* 8 (20) 98 (172)* 98 (282)* 8 (20) 97(170)* 99 (284)* 6 (10)
Carotid intima-media
thickness (mm)
0.99  0.15* 1.01  0.12* 0.91  0.09 0.99  0.18* 1.01  0.10* 0.91  0.11 1.01  0.11* 1.01  0.11* 1.0  0.07 1.0  0.11* 1.02  0.10* 1.0  0.12
Interventricular
septum (mm)
10.9  1.2 11.1  1.2 10.5  1.0 11.0  1.0 11.0  1.3 10.8  0.9 11.0  1.1 11.2  1.0 10.9  1.1 11.0  11 11.1  1.4 10.7  0.9
Left atrial diameter
(mm)
38.8  2.9 39.1  2.8 38.6  1.5 38.9  2.2 39.4  29 38.8  1.2 39.1  2.1 39.3  2.9 39.1  1.1 38.9  3.9 38.7  2.2 38.2  1.2
Incidence of clinical
atrial ﬁbrillation,
% (n)
0 0 0 1.7 (3)*yz 0 0 6.8 (12)*yz 2.1 (6)*z 0 2.8 (5)*z 2.4 (7)*z 0
Values are n, mean  SD, or n (%). *p < 0.05 vs. control group. yp < 0.5 vs. non-SAFE group. zvs. baseline data.
Non-SAFE Group ¼ no episodes of silent atrial ﬁbrillation; SAFE Group ¼ episodes of silent atrial ﬁbrillation.
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Figure 1 Linear Regression Between SCI Lesions and Episodes of AF
(A) The linear regression between the AF burden and the number of SCI lesions. (B) The linear regression between the AF burden and the area of SCI lesions.
AF ¼ atrial ﬁbrillation; SCI ¼ silent cerebral infarct.
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529association, the brief episodes of AF seem to have a pivotal
role. It seems likely that SCI exists more frequently in type 2
diabetic patients with silent episodes of AF than in subjects
without it, because 61% of patients in the SAFE group
had SCI compared with 29% in the non-SAFE group.
Intriguingly, because the OR in our population was 4.41, the
results of our study suggest that silent episodes of AF were an
independent determinant of SCI. Moreover, the risk of SCI
was higher when subclinical episodes of AF were of longer
duration, as evidenced by a positive correlation between AFTable 2
Multiple Logistic Regression Analysis for
Silent Cerebral Infarcts
Independent
Variable
Odds
Ratio
5% Lower
Conﬁdence
Interval
95% Upper
Conﬁdence
Interval p Value
Age 1.005 0.965 1.047 0.793
Silent episodes of
atrial ﬁbrillation
4.441 2.418 8.157 0.001
Interventricular
septum
0.886 0.736 1.068 0.204
Left atrial diameter 2.667 1.476 4.821 0.024
Duration of diabetes 1.075 1.002 1.154 0.044
Hemoglobin A1c 0.688 0.468 1.355 0.134
Fasting glucose 0.889 0.699 1.025 0.158
Post-prandial glucose 1.010 0.999 1.022 0.203
Carotid intima-media
thickness
0.273 0.0528 1.411 0.121
Body mass index 0.743 0.657 1.841 0.168
Systolic blood
pressure
1.030 1.010 1.050 0.002
Diastolic blood
pressure
0.975 0.939 1.012 0.179
Heart rate 0.973 0.944 1.002 0.069
Cholesterol 0.997 0.987 1.008 0.616
Triglycerides 0.991 0.979 1.004 0.164
High-density
lipoprotein
cholesterol
0.945 0.877 1.017 0.130burden and SCI. Notably, our data are consistent with
previous observations that SCI is associated with an increased
risk of subsequent stroke in patients with AF (15). However,
previous studies did not evaluate the role of brief episodes of
AF in cerebrovascular diseases in type 2 diabetic patients. In
our study, the baseline prevalence of SCI was associated with
stroke risk in patients in the SAFE group. According to our
data, the presence of SCI increased the risk of subsequent
stroke by 2 to 4 times in the general population, indepen-
dently of cardiovascular risk factors (16,17). Furthermore,
SCI is reported to be a strong predictor of subsequent clin-
ical stroke (approximate OR: 6 to 10) (18,19) and can be
considered the most important diabetic target organ damage
marker for stroke. In light of the data presented here, silent
brain infarcts should not be considered just intermediates in
the relationship between vascular risk factors and the risk ofFigure 2 Kaplan-Meier Curves for Adverse Events
Kaplan-Meier curves for the unadjusted rate of occurrence of stroke in patients
with or without silent episodes of atrial ﬁbrillation.
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530stroke but markers for other factors, such as brief episodes of
AF, that lead to stroke.
During a mean follow-up period of 37 months, stroke
developed in approximately 9% of the diabetic patients while
they were receiving therapy with antiplatelet agents. The
SAFE group had a higher incidence of stroke (15%) than the
non-SAFE group (5%). Furthermore, the annual risk of
stroke was even higher (3.5% to 6.8%) in diabetic patients in
the SAFE group compared with diabetic patients in the non-
SAFE group. This incidence is 2-fold higher than that seen
in diabetic patients without silent episodes of AF (1.4% to
2.1%) and comparable to the previously observed incidence of
stroke (approximately 8%) in patients with type 2 diabetes and
cardiovascular complications (2). In the present study, brief
episodes of AF were cross-sectionally signiﬁcantly associated
with the baseline prevalence of SCI detected by MRI of the
brain and prospectively with stroke events in type 2 diabetic
patients who did not have clinical AF.
Study limitations. Despite the relatively large number of
asymptomatic episodes of AF documented in this prospec-
tive study by quarterly 48HM, the study could be under-
powered for the technical approach used. Indeed, even if
standardized recording technique were used, it is possible
that many silent episodes of AF were missed. This could
explain the relatively high risk of cerebrovascular events in
those patients without documented AF. Strong evidence
suggests that a commonly used intermittent follow-up
strategy (24-h electrocardiographic Holter monitoring) is
signiﬁcantly inferior to full disclosure heart rhythm obser-
vation by implantable continuous cardiac rhythm moni-
toring with respect to detection of AF recurrence (20).
However, quarterly 48HM may improve the heart rhythm
investigations. In addition, we could not use continuous
heart rhythm surveillance in our population because there
was no indication for a device implanted subcutaneously.
Finally, on the basis of our data, we cannot establish
a temporal link between the episodes of AF and cerebro-
vascular disease. The SCIs are probably due to similar
AF that occurred in patients with silent AF before this
study.Conclusions
However, further research in a larger sample of populations
is needed to conﬁrm the reproducibility of our new ﬁndings.
The identiﬁcation of “brief episodes of AF” in type 2 dia-
betic patients may have clinical relevance in the identiﬁca-
tion of patients at risk and in the implementation of
preventive measures for stroke, even after assessment of
target organ damage.
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